Back to Search Start Over

Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative

Authors :
Fabian M. Johnston
Keith Fournier
Tiffany C. Lee
Shelby Speegle
Adriana C. Gamboa
T. Clark Gamblin
Laura A. Lambert
Rachel M. Lee
Callisia N. Clarke
Nadege Fackche
Courtney Pokrzywa
Jordan M. Cloyd
Ryan J. Hendrix
Nikhil V. Kotha
Mohammad Y. Zaidi
Sophie Dessureault
Charles A. Staley
Kaitlyn J. Kelly
Travis E. Grotz
Sameer H. Patel
Sean P. Dineen
Andrew J. Lee
Maria C. Russell
Sean M. Ronnekleiv-Kelly
Jennifer L. Leiting
Byrne Lee
Charles W. Kimbrough
Shishir K. Maithel
Andrew M. Blakely
Source :
Ann Surg Oncol
Publication Year :
2019

Abstract

Background For patients with peritoneal carcinomatosis undergoing cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC), incomplete cytoreduction (CCR2/3) confers morbidity without survival benefit. The aim of this study is to identify preoperative factors which predict CCR2/3. Methods All patients who underwent curative-intent CRS/HIPEC of low/high-grade appendiceal, colorectal, or peritoneal mesothelioma cancers in the 12-institution US HIPEC Collaborative from 2000 to 2017 were included (n = 2027). The primary aim is to create an incomplete-cytoreduction risk score (ICRS) to predict CCR2/3 CRS utilizing preoperative data. ICRS was created from a randomly selected cohort of 50% of patients (derivation cohort) and verified on the remaining patients (validation cohort). Results Within our derivation cohort (n = 998), histology was low-grade appendiceal neoplasms in 30%, high-grade appendiceal tumor in 41%, colorectal tumor in 22%, and peritoneal mesothelioma in 8%. CCR0/1 was achieved in 816 patients and CCR 2/3 in 116 patients. On multivariable analysis, preoperative factors associated with incomplete cytoreduction were male gender [odds ratio (OR) 3.4, p = 0.007], presence of ascites (OR 2.8, p = 0.028), cancer antigen (CA)-125 ≥ 40 U/mL (OR 3.4, p = 0.012), and carcinoembryonic antigen (CEA) ≥ 4.2 ng/mL (OR 3.2, p = 0.029). Each preoperative factor was assigned a score of 0 or 1 to form an ICRS from 0 to 4. Scores were grouped as zero (0), low (1-2), or high (3-4). Incidence of CCR2/3 progressively increased by risk group from 1.6% in zero to 13% in low and 39% in high. When ICRS was applied to the validation cohort (n = 1029), this relationship was maintained. Conclusion The incomplete cytoreduction risk score incorporates preoperative factors to accurately stratify the risk of CCR2/3 resection in CRS/HIPEC. This score should not be used in isolation, however, to exclude patients from surgery.

Details

ISSN :
15344681
Volume :
27
Issue :
1
Database :
OpenAIRE
Journal :
Annals of surgical oncology
Accession number :
edsair.doi.dedup.....9fa898771d1a34137f9e38860cf3032d